Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
01 8Atozet
02 1Caduet
03 4Gadavist/Gadovist
04 2Gadovist product family
05 16Lipitor
06 3Nilemdo/Nustendi
07 2Rosuzet
08 5Vytorin
09 9Zetia
10 1ZetiaTM
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 466
2019 Revenue in Millions : 524
Growth (%) : -11
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 460
2020 Revenue in Millions : 466
Growth (%) : 9
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular
Currency : USD
2014 Revenue in Millions : -2.30%
2013 Revenue in Millions :
Growth (%) :
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 453
2016 Revenue in Millions : 429
Growth (%) : 5
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 414
2017 Revenue in Millions : 412
Growth (%) : 0%
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 367
2015 Revenue in Millions : 307
Growth (%) : 19
Bayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 436
2018 Revenue in Millions : 399
Growth (%) : 9
